Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

The study period per participant was approximatively 128 weeks broken down as follows: * Screening period up to 4 weeks, * 108-week double-blind treatment period (approximatively 2 years)\*, * 16-week post-treatment elimination follow-up period. '\*' Participants successfully completing the week 108 visit were offered the opportunity to enter the optional long-term extension study LTS6050 - NCT00803049.